Thanks to the multicentre, double-blind, randomized, placebo-controlled clinical trials in the last 5 years a significant progress in the therapy of relapsing-remitting multiple sclerosis was achieved. The aim of steroid therapy is to reduce the rate of acute exacerbations. The first-choice recommended therapeutical strategy is the megadosis steroid therapy according to the Longitudinal Optic Neuritis Study. Drugs are available nowaday to reduce the progression of the disease: interferon-β-1a interferon-β-1b and glatirameracetate. The new therapeutic possibilities provide us to slow down the progression of multiple sclerosis and to delay the worsening of patient's condition.
|Translated title of the contribution||Therapy of relapsing-remitting multiple sclerosis|
|Number of pages||5|
|Journal||Lege Artis Medicinae|
|Publication status||Published - Dec 1 1998|
ASJC Scopus subject areas